| 15 |
范晓春，屠 苏，曹赋韬. 参麦注射液对重症肺炎患者炎症因子影响[J]. 河北医学，2018, 24(10): 1656-1659.
|
| 16 |
中华医学会呼吸病学分会. 中国成人社区获得性肺炎诊断和治疗指南(2016年版)[J]. 中华结核和呼吸杂志，2016, 39(4): 253-279.
|
| 17 |
郑莜萸. 中药新药临床研究指导原则(试行)[S]. 北京：中国医药科技出版社，2002: 34-8.
|
| 18 |
则学英，安春霞，刘 磊. 利奈唑胺联合美罗培南治疗重症肺炎疗效观察及对患者肺泡灌洗液中miR-127-5p、miR-3686表达的影响[J]. 中国药师，2021, 24(5): 884-888.
|
| 19 |
Simkovich SM, Underhill LJ, Kirby MA, et al. Resources and geographic access to care for severe pediatric pneumonia in four resource-iimited settings[J]. Am J Respir Crit Care Med, 2022, 205(2): 183-197.
|
| 20 |
虎盘林，赵海平，董剑虹. 美罗培南不同输注时间治疗老年住院患者获得性肺炎的临床效果比较[J/CD]. 中华肺部疾病杂志(电子版), 2020, 13(1): 75-77.
|
| 21 |
周海芳，叶远玲，王瑞明. 参麦注射液联合美罗培南对老年重症感染患者细胞免疫功能、炎症因子及肺功能的影响[J]. 中国老年学杂志，2018, 38(8): 1885-1887.
|
| 22 |
Caro-Codón J, Rey JR, Buño A, et al. Characterization of NT-proBNP in a large cohort of COVID-19 patients[J]. Eur J Heart Fail, 2021, 23(3): 456-464.
|
| 23 |
Mendoza M, Garcia-Ruiz I, Maiz N, et al. Pre-eclampsia-like syndrome induced by severe COVID-19: a prospective observational study[J]. BJOG, 2020, 127(11): 1374-1380.
|
| 24 |
Wang S, Dong Y, Wang J, et al. The protective effect of ulinastatin combined with Xuebijing on myocardial injuries in patients with severe pneumonia[J]. Am J Transl Res, 2021, 13(10): 11745-11751.
|
| 25 |
崔 颖，高天宇，贾月霞，等. 益元清肺汤联合西药对老年重症肺炎(气虚肺热证)呼吸支持患者炎症反应及免疫功能的影响[J]. 陕西中医，2022, 43(7): 880-883.
|
| 26 |
肖红雯，彭 勇，周洪伟，等. 血必净注射液联合哌拉西林钠舒巴坦治疗老年重症肺炎的疗效及其对炎性因子和免疫功能的影响[J]. 中国老年学杂志，2021, 41(19): 4218-4221.
|
| 27 |
郭张妍，刘莎莎，王 娟. 免疫功能低下患儿重症肺炎的临床特点及预后危险因素研究[J]. 国际儿科学杂志，2021, 48(11): 790-794.
|
| 28 |
谢 辉，冯 俊，黄秋杰，等. 乌司他丁联合参麦注射液治疗对重症肺炎患者心肌损伤保护及肺功能的影响[J]. 实用医学杂志，2022, 38(10): 1260-1264.
|
| 29 |
Rachina S, Bobylev A, Lazarev P, et al. Biomarker value in the diagnosis of community-acquired pneumonia with concomitant chronic heart failure[J]. J Clin Med, 2021, 10(19): 4570.
|
| 30 |
Ni M, Tian FB, Xiang DD, et al. Characteristics of inflammatory factors and lymphocyte subsets in patients with severe COVID-19[J]. J Med Virol, 2020, 92(11): 2600-2606.
|
| 1 |
Cilloniz C, Pericàs JM, Rojas J. Ceftaroline in severe community-acquired pneumonia[J]. Rev Esp Quimioter, 2022, 35 (Suppl 1): 28-30.
|
| 2 |
Qu J, Zhang J, Chen Y, et al. Aetiology of severe community acquired pneumonia in adults identified by combined detection methods: a multi-centre prospective study in China[J]. Emerg Microbes Infect, 2022, 11(1): 556-566.
|
| 3 |
Forteza Guillot M, Martín Cerezuela M, Ramírez P. New evidence in severe pneumonia: meropenem-vaborbactam[J]. Rev Esp Quimioter, 2022, 35 (Suppl 1): 43-45.
|
| 4 |
Rochwerg B. Corticosteroids for severe community-acquired pneumonia：a story without an ending[J]. Intensive Care Med, 2022, 48(8): 1053-1055.
|
| 5 |
Dai N, Li Q, Geng J, et al. Severe pneumonia caused by Chlamydia psittaci: report of two cases and literature review[J]. J Infect Dev Ctries, 2022, 16(6): 1101-1112.
|
| 6 |
Burillo A, Candel FJ, Canut-Blasco A. Value of syndromic panels in the management of severe community-acquired pneumonia[J]. Rev Esp Quimioter, 2022, 35 (1): 15-20.
|
| 7 |
Kaneta A, Sato T, Nakano H, et al. Preoperative bacterial culture can predict severe pneumonia in patients receiving esophagectomy[J]. Fukushima J Med Sci, 2022, 68(2): 109-116.
|
| 8 |
郭 枫，乐道平，陈 晶，等. 乌司他丁联合美罗培南对老年重症肺炎患者炎症介质和氧化应激的影响[J]. 中国老年学杂志，2022, 42(9): 2134-2136.
|
| 9 |
黎代强，陈 琳，缪锦松，等. 乌司他丁联合美罗培南治疗老年重症肺炎的疗效及对患者肺氧合功能及血清C反应蛋白、降钙素原水平的影响[J]. 海南医学，2022, 33(1): 17-20.
|
| 10 |
杨 梅，严永俊，岳 凤，等. 亚胺培南西司他丁钠与美罗培南治疗重症肺炎临床疗效与安全性比较[J]. 中国药物与临床，2021, 21(14): 2438-2440.
|
| 11 |
何金波，毛峥嵘，宋鹏阳. 加味宣白承气汤治疗重症肺炎合并急性胃肠损伤的临床研究[J]. 南京中医药大学学报，2022, 38(2): 103-108.
|
| 12 |
陈 韵，张星星，高志凌，等. 清金化痰汤加减辅助抗生素治疗老年重症肺炎疗效及对患者炎症反应递质的影响[J]. 陕西中医，2022, 43(5): 580-583.
|
| 13 |
孙 青，钱培培，郝明泽，等. 清肺化痰针刺法联合桑白皮汤加味治疗重症肺炎(痰热壅肺证)的疗效研究[J]. 中国中医急症，2022, 31(4): 651-654.
|
| 14 |
杨广亮，张震环. 小剂量氢化可的松联合参麦注射液治疗老年重症肺炎临床效果观察[J]. 临床军医杂志，2019, 47(6): 636-637.
|